AKYNZEO® inhibits 2 nausea and vomiting pathways

As a single agent in the preclinical analysis, AKYNZEO inhibited the receptors that drive acute (Day 1) and delayed (up to Day 5) CINV1

MOA Diagram
*Observed in clinical studies of cancer patients.
Based on netupitant concentration after IV injection.

AKYNZEO drug components have demonstrated emetic receptor inhibition in a preclinical study2

  • Palonosetron was shown to potentiate NK-1 receptor internalization in cells pretreated with netupitant2‡
  • Fosnetupitant, a prodrug of netupitant, is converted in vivo to netupitant1

AKYNZEO combines 2 agents for inhibitor activities across the continuum of acute and delayed CINV1

The correlation between these pharmacological data and clinical efficacy has not been established.

  • 5-HT3 RA=5-HT3 receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; NK-1 RA=neurokinin-1 receptor antagonist.
  • Based on the results of an in vitro study with a cell line expressing both the 5-HT3 and NK-1 receptors (NG108-15).